JP2006506955A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506955A5
JP2006506955A5 JP2004501459A JP2004501459A JP2006506955A5 JP 2006506955 A5 JP2006506955 A5 JP 2006506955A5 JP 2004501459 A JP2004501459 A JP 2004501459A JP 2004501459 A JP2004501459 A JP 2004501459A JP 2006506955 A5 JP2006506955 A5 JP 2006506955A5
Authority
JP
Japan
Prior art keywords
seq
cdr
antibody molecule
sequence shown
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004501459A
Other languages
English (en)
Japanese (ja)
Other versions
JP4486494B2 (ja
JP2006506955A (ja
Filing date
Publication date
Priority claimed from GBGB0210121.0A external-priority patent/GB0210121D0/en
Application filed filed Critical
Publication of JP2006506955A publication Critical patent/JP2006506955A/ja
Publication of JP2006506955A5 publication Critical patent/JP2006506955A5/ja
Application granted granted Critical
Publication of JP4486494B2 publication Critical patent/JP4486494B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004501459A 2002-05-02 2003-05-02 生物学的製剤 Expired - Lifetime JP4486494B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products
PCT/GB2003/001934 WO2003093320A2 (en) 2002-05-02 2003-05-02 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009205660A Division JP5377173B2 (ja) 2002-05-02 2009-09-07 生物学的製剤

Publications (3)

Publication Number Publication Date
JP2006506955A JP2006506955A (ja) 2006-03-02
JP2006506955A5 true JP2006506955A5 (https=) 2008-10-23
JP4486494B2 JP4486494B2 (ja) 2010-06-23

Family

ID=9935990

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004501459A Expired - Lifetime JP4486494B2 (ja) 2002-05-02 2003-05-02 生物学的製剤
JP2009205660A Expired - Lifetime JP5377173B2 (ja) 2002-05-02 2009-09-07 生物学的製剤
JP2013140245A Expired - Lifetime JP5920934B2 (ja) 2002-05-02 2013-07-04 生物学的製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009205660A Expired - Lifetime JP5377173B2 (ja) 2002-05-02 2009-09-07 生物学的製剤
JP2013140245A Expired - Lifetime JP5920934B2 (ja) 2002-05-02 2013-07-04 生物学的製剤

Country Status (34)

Country Link
US (8) US7355011B2 (https=)
EP (1) EP1504035B9 (https=)
JP (3) JP4486494B2 (https=)
KR (3) KR101386376B1 (https=)
CN (3) CN101134779B (https=)
AT (1) ATE462729T3 (https=)
AU (1) AU2003223007C1 (https=)
BE (1) BE2017C068I2 (https=)
CA (1) CA2484420C (https=)
CO (1) CO5631451A2 (https=)
CY (3) CY1110134T1 (https=)
DE (1) DE60331910D1 (https=)
DK (1) DK1504035T6 (https=)
EC (1) ECSP045470A (https=)
ES (1) ES2341708T7 (https=)
FR (1) FR17C1062I2 (https=)
GB (1) GB0210121D0 (https=)
HU (2) HUS1700055I1 (https=)
IL (1) IL164923A (https=)
LT (2) LTC1504035I2 (https=)
LU (2) LUC00057I2 (https=)
MX (1) MXPA04010787A (https=)
NL (1) NL300920I2 (https=)
NO (3) NO336201B3 (https=)
NZ (1) NZ536757A (https=)
PL (1) PL218433B1 (https=)
PT (1) PT1504035E (https=)
RU (1) RU2342401C2 (https=)
SG (1) SG161744A1 (https=)
SI (1) SI1504035T1 (https=)
TW (1) TWI324161B (https=)
UA (1) UA92580C2 (https=)
WO (1) WO2003093320A2 (https=)
ZA (1) ZA200408851B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461351C (en) * 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
SI2371392T1 (sl) * 2002-05-02 2015-10-30 Wyeth Holdings Llc Konjugati derivat-nosilec kaliheamicina
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GT200500283A (es) * 2004-10-08 2006-05-08 Inmunoterapia de desordenes autoinmunes
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP2650306A1 (en) * 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2644906C (en) * 2006-03-06 2016-05-10 Medimmune, Inc. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
EP2841459A4 (en) * 2012-04-26 2016-04-13 Bioatla Llc ANTI-CD22 ANTIBODIES
HK1209768A1 (en) 2012-07-03 2016-04-08 Washington University Antibodies to tau
KR102165464B1 (ko) 2012-07-19 2020-10-14 레드우드 바이오사이언스 인코포레이티드 Cd22에 대해 특이적인 항체 및 이들의 사용 방법
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
MX2017012939A (es) * 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
KR102783230B1 (ko) 2015-11-09 2025-03-19 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
CN112888709B (zh) 2018-03-30 2024-10-29 优瑞科生物技术公司 标靶cd22的构建体和其用途
US12448453B2 (en) * 2020-04-02 2025-10-21 Nanjing IASO Biotechnology Co., Ltd. Fully human anti-human CD22 chimeric antigen receptor and application thereof
US20230331840A1 (en) * 2020-08-27 2023-10-19 Fapon Biotherapy Inc. Cd22 antibody and application thereof
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
JP2024534148A (ja) * 2021-08-27 2024-09-18 ペプトロン インコーポレイテッド 新規抗ｍｕｃ１抗体およびその用途
CN116217727B (zh) * 2021-12-06 2025-04-29 重庆精准生物技术有限公司 靶向cd22的抗原结合片段和单链抗体及其应用
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2264239T3 (es) * 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
EP0531472B1 (en) * 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
EP0804237B8 (en) 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
ES2251723T3 (es) * 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2270288A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP0970227B1 (en) 1997-03-20 2008-01-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
CA2375912C (en) * 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
PT1232392E (pt) * 1999-10-12 2003-08-29 Connex Ges Optimierung Von For Processo melhorado para deteccao nas fezes de bacterias do genero helicobacter resistentes ao acido
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
SG136804A1 (en) * 2000-07-12 2007-11-29 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SI2371392T1 (sl) 2002-05-02 2015-10-30 Wyeth Holdings Llc Konjugati derivat-nosilec kaliheamicina
EP2650306A1 (en) * 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Similar Documents

Publication Publication Date Title
JP2006506955A5 (https=)
RU2004135103A (ru) Антитела, специфичные к cd22 человека, и их применения в терапии и диагностике
TWI769537B (zh) 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途
US6676924B2 (en) CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
KR101681910B1 (ko) Ｒｇｍ ａ 단백질에 대한 모노클로날 항체 및 이의 용도
AU2015322141B2 (en) High affinity and aggregatively stable antibodies on the basis of variable domains Vl and a derivative VHH
JP2010022372A5 (https=)
KR920702425A (ko) Cdr 이식된 항-cea 항체 및 그의 제조
CA2420231A1 (en) Antibodies to human il-1.beta.
RU2008149918A (ru) Антитела к nkg2a и их применения
RU2012130840A (ru) Соединения
RU2008129787A (ru) Фармацевтические композиции с устойчивостью к растворимому сеа
RU2010133892A (ru) Гуманизированные моноклональные антитела против человеческого nkg2a
RU2004127458A (ru) Анти-cd20 антитела, их гибридные белки и способы их использования
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
JP2010524435A5 (https=)
JP2017535246A5 (https=)
US20230312742A1 (en) CD38 antibodies for the treatment of human diseases
RU2005121669A (ru) Анти-nogo антитела ("11с7") и их фармацевтическое использование
JPWO2020139926A5 (https=)
CA2538725A1 (en) Nogo-a binding molecules and pharmaceutical use thereof
CN110563847A (zh) 用于治疗性用途的免疫检查点抑制剂
JPWO2021139780A5 (https=)
JPWO2020143749A5 (https=)
RU2025110616A (ru) CD163 Связывающий белок